Healio’s top five ophthalmic business items
Click Here to Manage Email Alerts
Catch up on Healio’s top five items in ophthalmic business from May.
Hot topics include de novo authorization for an AI-powered remote OCT device, FDA approvals for aflibercept biosimilars and Merck’s acquisition of EyeBio.
Image: Adobe Stock
Merck to acquire EyeBio
Restoret, EyeBio’s lead candidate for diabetic macular edema and wet age-related macular degeneration, is part of the acquisition, which is potentially valued at $3 billion. Read more.
Bausch + Lomb receives Canadian approval for enVista Envy IOL
A decision from the FDA on U.S. approval is expected later this year. Read more.
FDA approves aflibercept biosimilars Yesafili, Opuviz
Yesafili and Opuviz showed no clinically meaningful differences in efficacy, safety or immunogenicity from Eylea. Read more.
FDA grants de novo authorization to AI-powered Scanly Home OCT device
The device will allow patients with wet age-related macular degeneration to obtain OCT images at home. Read more.
VIDEO: Oculis CEO delivers updates on OCS-01 eye drop trials for DME
Riad Sherif, MD, CEO of Oculis, discusses the company’s two phase 3 clinical trials for the OCS-01 eye drop. Watch here.
Collapse
Healio Coverage
Click Here to Manage Email Alerts